Sanofi's Sarclisa Gets EU Nod for On-Body Injector, First Anticancer Treatment with Home Option
SNY is trading near its 52-week low of $42.28 (6.5% above the low).
Summary
The European Commission has approved Sanofi's Sarclisa subcutaneous formulation for multiple myeloma, to be administered via an on-body injector. This marks the first anticancer treatment in the EU available through such a device, offering patients the flexibility of home or outpatient administration. This final approval follows a positive recommendation from the European Medicines Agency's CHMP in March. The enhanced convenience and reduced burden on healthcare systems could significantly boost Sarclisa's market adoption and patient adherence.
At the time of this announcement, SNY was trading at $45.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $108.3B. The 52-week trading range was $42.28 to $52.68. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.